Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Second Formulation Clear all
Recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530
View directory record Official record
Conditions
Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects

NCT00834795
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol 25 mg tablets, COREG® 25 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00730158
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
KD018, Irinotecan, Placebo
Drug
Lead sponsor
Edward Chu, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 8, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05460533
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Day to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 4 Interventional

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

NCT00334048
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Ropinirole (Requip)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Preferences of Consumers and Clinicians for the Management of Shave Biopsy Sites With a PolyMem Formulation Dressing or Current Standard of Care.

NCT00727870
View directory record Official record
Conditions
Healing
Interventions
Shapes by PolyMem dressing, Shapes by PolyMem Silver Dressing, Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site
Device
Lead sponsor
Ferris Mfg. Corp.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 8, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT06998940
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
274
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

NCT02994602
View directory record Official record
Conditions
Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Not listed Phase 1Phase 2 Interventional Results available

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

NCT03337087
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)

NCT01152073
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Second Formulation, Third Formulation
Dietary Supplement
Lead sponsor
Healthy Drink Discoveries, Inc.
Other
Eligibility
20 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

NCT04109222
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 83 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Taste Evaluation of Different Liquid Formulations With Eliglustat

NCT02422654
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

NCT05543928
View directory record Official record
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions
CTAP101, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Columbus, Ohio • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

NCT03878927
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CPX-351, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

NCT01039883
View directory record Official record
Conditions
Onychomycosis
Interventions
Albaconazole tablet 400mg, Albaconazole 100mg capsules, then albaconazole 400mg tablet
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

NCT00976820
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 8 Years
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
17
States / cities
Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects

NCT03005041
View directory record Official record
Conditions
Xerostomia
Interventions
Biotene mouthwash, Bottled mineral water
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 84 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 8, 2026, 2:48 AM EDT